OBI Pharma is excited to announce that Dr. Ming-Tain Lai, Chief Scientific Officer, has been invited to present an oral presentation at the upcoming 14th World ADC conference in London, United Kingdom.
This conference will be held on March 12th-15th, 2024. It united 800+ leading players in the field under one roof, including experts from major pharmaceutical companies, biotech, and academic institutions. The World ADC Event Series is the largest academic event in the global ADC (Antibody-Drug Conjugate) field.
Dr. Lai’s title is “OBI-992: An Anti-TROP2 ADC With Distinct Properties.” Dr. Lai will be presenting at a Speaker Session on Thursday, March 14, 2024 at 2:30 PM London time. He will share the following:
- Exploring the in vitro characterization of the ADC
- Discussing in vivo animal efficacy studies of the ADC
- Analyzing the pharmacokinetics/pharmacodynamics of the ADC
OBI-992 is a TROP2-targeted ADC that carries a potent topoisomerase I inhibitor payload to kill tumor cells. TROP2 is highly expressed in a variety of solid tumors such as lung, breast, ovarian, and gastric cancer, rendering it an ideal target for cancer therapy.
OBI-992 uses a unique hydrophilic, enzyme-cleavable linker that is stable in circulation but releases the cytotoxic payload inside tumor cells. OBI-992 demonstrates remarkable antitumor efficacy, improved pharmacokinetic characteristics, and a favorable safety profile in animal models. The US FDA has cleared an Investigational New Drug (IND) application for OBI-992 in January 2024. The Phase 1/2 efficacy and safety human studies are planned to commence Q2,2024.
The TROP2 targeting antibody was in-licensed from Biosion, Inc. , in December 2021. OBI Pharma owns ex-China commercial rights for OBI-992.